Axion Biosystems is a global life science tools business with headquarters in the US, developing, producing, and marketing BEA (Bioelectronic Assay) and live-cell imaging instruments for customers in biopharma and academia. Axion’s products enable scientists to understand cell function in real-time, enabling research and the development of new therapies across various pharmaceutical segments (e.g., cell and gene therapies).
Axion
Overview
Axion at a glance
Key developments 2022
Axion acquired M-Solv in January 2022, bringing production of consumables plates in-house with positive effects on gross margins. Axion also acquired CytoSMART in March 2022, allowing Axion to expand into the next-gen live-cell imaging market. Axion also developed two products, TrayZ and Omni 12 Pro, during 2022, which are being launched in Q1 2023, enabling new growth levers.
Sector
Life sciences tools
Location
United States
SDG aligment
Environmental
Carbon intensity: Tons CO₂e per EUR m revenue
Total tons CO₂ emitted
Change from '21-'22
2022
+0%
1 868
2021
1 437
Monetized climate impact
-EURm
The figure represents the monetized value the company has on the environment. See chapter 4 for methodology.
Social
Full time employees
Turnover7%
Unadjusted gender pay gap18%
Gender balance, % females
%
Board
%
Management
%
All employees
Monetized employment impact
EURm
The figure represents the monetized value the company has as a quality employer. See chapter 4 for methodology.
Governance
Via Summa Compliance
%
✔ Code of conduct
✔ Supplier code of conduct
✔ Economic Sanctions
✔ Competition Law/Antitrust
✔ Data Protection/IT Security
✔ Anti-curruption
✔ Whistleblower
Science Based Targets
Axion has committed to Science Based Targets and received target validation April 2023. The company commits to reduce scope 1 and scope 2 GHG emissions 42% by 2030 compared to 2022 as base year, and to measure and reduce its scope 3 emissions.
Board Gender Diversity
Plan to improve gender diversity towards 40% has been initiated, target to achieve this during 2023.
What are the challenges Axion addresses?
~0bn
average cost of getting a drug onto the market
0/0
deaths are due to Cancer globally, making it one of the leading causes of death worldwide
How does Axion help?
Reality today
Healthcare systems need better tools to understand cell function in order to target diseases and drive patient outcomes.
Axion approach
Axion enables multi-dimensional, interoperable live-cell analysis to improve drug discovery and development, drive breakthroughs in cell and gene therapies, and ultimately enable superior health outcomes.
Aspirational future
Faster, more accurate and more cost-efficient drug discovery and development for precision medicine.
What impact does Axion create?
Number of publications
Change from '21-'22
Target 2026: 406
2022
+0%
178
2021
158
2020
92
Number of systems sold to Cell Gene Therapy companies
Change from 21-'22
Target 2026: 50
2022
+0%
22
2021
12
2020
12
Number of experiments run
Change from '21-'22
Target 2026: 1 974 k
2022
+0%
790k
2021
652k
2020
456k
Who is impacted?
Researchers and biopharma are impacted directly through more effective tools to understand cell function. Patients are impacted indirectly through breakthroughs in treatment developments.
What are the impact considerations?
Additionality
Without Axion, academia and biopharma would have less insight into cell function, slowing down the time and reducing the quality of critical drug development.
Risks
Axion’s impact depends in part on how its customers in academia and biopharma choose to use its tools. Axion can engage customers to help ensure that the research and innovation it enables translates into patient outcomes downstream.